Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...

The Company encourages use of the webcast due to potential extended wait times to access the conference call via dial-in. The webcast of the conference call will be available in the Investor Relations ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

As the S&P 500 hovers near record highs and treasury yields drop following retail sales data, investors are keeping a close eye on the broader U.S. market trends. Penny stocks, often associated with ...

U.S. stocks traded higher toward the end of trading, with the Dow Jones index surging more than 100 points on Thursday. The ...

European shares were mostly higher today. The eurozone's STOXX 600 rose 1.01%, Germany's DAX 40 rose 1.77% and France's CAC ...

Dr. Pardeep Nijhawan ("Dr. Nijhawan") and Velan Capital jointly announce updates to their beneficial ownership of securities of Edesa Biotech, Inc. ("Edesa") in accordance with "early warning" ...

The New York Stock Exchange is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update?for market insights before trading begins.  Kristen ...

TORONTO - Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has announced the completion of a private placement funding round on February 12, 2025, raising approximately ...

Edesa Biotech (EDSA) announced that it has sold, in a private placement, an aggregate of 834 newly designated Series B-1 convertible preferred ...